Mechanisms of Action

GLP-1 receptor agonist medicines exert their effects by binding to GLP-1 receptors located on pancreatic beta-cells, promoting glucose-dependent insulin secretion. This mechanism helps maintain balanced insulin release without significantly increasing hypoglycemia risk during normal glucose levels. They also suppress glucagon release from alpha-cells specifically during periods of hyperglycemia, contributing to improved glucose regulation.

Additional actions include delaying gastric emptying, which can promote a sense of satiety through central nervous system pathways that regulate appetite. These medicines influence food intake via hypothalamic modulation and interactions with peripheral gut hormones. Research further indicates enhancements in insulin sensitivity and potential cardiovascular benefits through improved endothelial function.

Dual and triple agonists, such as tirzepatide (GLP-1/GIP) or those incorporating glucagon receptor activation, offer enhanced effects on weight management and metabolic flexibility. These multi-receptor approaches aim to amplify satiety signals while preserving lean mass and supporting energy expenditure.

These statements have not been evaluated by the Food and Drug Administration. These mechanisms are supported by research and not intended to diagnose, treat, cure, or prevent any disease.